(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Celcuity's revenue in 2026 is $0.On average, 12 Wall Street analysts forecast CELC's revenue for 2026 to be $2,093,195,380, with the lowest CELC revenue forecast at $477,909,622, and the highest CELC revenue forecast at $4,020,195,250. On average, 12 Wall Street analysts forecast CELC's revenue for 2027 to be $20,308,720,638, with the lowest CELC revenue forecast at $11,149,436,425, and the highest CELC revenue forecast at $35,382,380,258.
In 2028, CELC is forecast to generate $37,962,604,556 in revenue, with the lowest revenue forecast at $20,789,068,574 and the highest revenue forecast at $63,103,576,672.